Paragonix Technologies Inc., Announces Award of a Phase I Small Business Innovation Research (SBIR) Grant to Support the Pre-Clinical Development of the Paragonix Sherpa Cardiac Transport System
7/16/2012 10:01:42 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Paragonix Technologies Inc., today announced that the National Heart, Blood and Lung Institute has awarded a Phase I Small Business Innovation Research (SBIR) grant to the company to support the pre-clinical development of the Paragonix Sherpa™ Cardiac Transport System2,3. The Phase I SBIR grant is for a six month time period from July to December 2012. Successful completion of the Phase I SBIR grant will enable a SBIR Phase II application for up to $1,000,000.